Notable Labs Inc. (NTBL): Utang-utang marang kapitalisasi buku

The commercialization of predictive software requires time and external funding, which defines the current market dynamics of Notable Labs, Ltd. (NTBL). The share of debt financing in the balance sheet capitalization demonstrates the stability of the liability structure, with the metric valued at 0.00. The business's success relies on unique AI blood analysis patents, although development depends on algorithmic accuracy and partnerships with clinics.

Notable Labs, Ltd. (NTBL) - Utang-utang marang nilai buku saka 21.02.2024 nganti 02.11.2024

The financial stability of Notable Labs, Ltd. (NTBL) is determined by the balance between borrowed funds and equity. The dynamics of debt obligations relative to the balance sheet capital structure reflect the business's degree of dependence on creditors. This metric is calculated as the ratio of total debt to total asset value minus liabilities. For a company in the expansion phase of precision oncology, moderate leverage stimulates the scaling of the platform. A decrease in this ratio confirms the growth of the business's intrinsic value.

Karo sapa Notable Labs, Ltd. saingan

ONC - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku halozyme.com HALO|RVMD: Utang-utang marang kapitalisasi buku|AAPG - Utang marang nilai buku|Utang-utang marang kapitalisasi buku CGON|URGN (UroGen Pharma Corp) - Utang-utang marang nilai buku|BCAX - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik personalis.com (PSNL)|Erasca (ERAS) - Utang marang nilai buku|Rasio utang marang aset resik Delcath Systems Inc (DCTH)|YmAbs - Utang-utang marang kapitalisasi buku|AURA - Utang marang nilai buku|Candel - Utang marang nilai buku|ARAY: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku sellaslifesciences.com SLS|Actuate Therapeutics Inc. (ACTU) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku CTOR (Citius Oncology, Inc)|Utang-utang marang nilai buku HURA|Rasio utang marang kapitalisasi buku Protara Therapeutics TARA|Rasio utang marang nilai buku FATE (fatetherapeutics.com)|WHWK: Rasio utang marang kapitalisasi buku|TCRX - Utang-utang marang nilai buku|Utang marang nilai buku Champions Oncology Corp CSBR|XBIT - Utang marang modal buku|CVM: Utang-utang marang kapitalisasi buku|ostherapies.com (OSTX) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Radiopharm Theranostics Limited|Rasio utang marang kapitalisasi buku ARTV|Rasio utang marang kapitalisasi buku Adlai Nortye Ltd. (ANL)|Rasio utang marang kapitalisasi buku Veru Corporation (VERU)|TPST: Utang-utang marang kapitalisasi buku|XLO - Utang-utang marang nilai buku|Utang marang nilai buku Enochian BioSciences (RENB)|MURA: Rasio utang marang aset resik|kairospharma.com (KAPA) - Rasio utang marang kapitalisasi buku|OnKure Therapeutics (OKUR) - Rasio utang marang kapitalisasi buku|GDTC (CytoMed Therapeutics Ltd) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku Curis Corp|Utang-utang marang kapitalisasi buku Apollomics, Inc. (APLM)|Rasio utang marang kapitalisasi buku THAR (Tharimmune Inc)|Rasio utang marang kapitalisasi buku ADVB|GNPX - Utang-utang marang aset resik|Utang marang nilai buku Calidi Bio (CLDI)|SBFM: Rasio utang marang aset resik|xeneticbio.com (XBIO) - Rasio utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Salarius Pharmaceuticals Inc|Purple Biotech Corp (PPBT) - Utang marang nilai buku|Utang marang modal buku AON|Utang-utang marang kapitalisasi buku BeiGene, Ltd. BGNE|Rasio utang marang nilai buku checkpointtx.com CKPT|Utang marang nilai buku ELEV|iCAD Inc. - Utang-utang marang aset resik|Ikena (IKNA) - Rasio utang marang kapitalisasi buku|Viracta Therapeutics (VIRX) - Rasio utang marang nilai buku|MOR - Utang marang nilai buku|nayabiosciences.com (NAYA) - Utang marang modal buku|Utang-utang marang kapitalisasi buku Ascentage Pharma